touchneurology.com
Open in
urlscan Pro
2606:4700:3035::6815:d22
Public Scan
URL:
https://touchneurology.com/?p=37137&post_type=learning-zone&preview=1&_ppp=24144ac883
Submission: On January 30 via manual from US — Scanned from DE
Submission: On January 30 via manual from US — Scanned from DE
Form analysis 1 forms found in the DOM
POST
<form action="" class="js-form js-feedback-form-short" method="POST" novalidate="novalidate">
<input type="hidden" name="therapy_website" value="">
<input type="hidden" name="activity_url" value="https://touchneurology.com/parkinsons-disease/learning-zone/impact-of-delayed-on/">
<input type="hidden" name="activity_id" value="37137">
<div class="c-feedback is-active">
<div class="o-field js-toggle-field">
<label class="o-label o-label--large u-mb-2 o-field__label h6 u-text-grey u-text-500" for="feedback1">This activity was of high quality. *</label>
<span class="o-label--small">1= Strongly Disagree and 5= Strongly Agree</span>
<div class="o-field__columns">
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback1" value="1" class="o-toggle__field js-toggle-change u-hide required" required="">
<span class="o-toggle__box"></span>
<span class="o-toggle__label u-text-grey">1</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback1" value="2" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">2</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback1" value="3" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">3</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback1" value="4" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">4</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback1" value="5" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">5</span>
</label>
</div><!-- /.o-field__columns -->
<div class="o-error js-error-placement"></div><!-- /.o-error js-error-placement -->
</div><!-- /.o-field -->
<div class="o-field js-toggle-field">
<label class="o-label o-label--large u-mb-2 o-field__label h6 u-text-grey u-text-500" for="feedback2">This activity met the stated educational objectives. *</label>
<span class="o-label--small">1= Strongly Disagree and 5= Strongly Agree</span>
<div class="o-field__columns">
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback2" value="1" class="o-toggle__field js-toggle-change u-hide required" required="">
<span class="o-toggle__box"></span>
<span class="o-toggle__label u-text-grey">1</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback2" value="2" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">2</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback2" value="3" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">3</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback2" value="4" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">4</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback2" value="5" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">5</span>
</label>
</div><!-- /.o-field__columns -->
<div class="o-error js-error-placement"></div><!-- /.o-error js-error-placement -->
</div><!-- /.o-field -->
<div class="o-field js-toggle-field">
<label class="o-label o-label--large u-mb-2 o-field__label h6 u-text-grey u-text-500" for="feedback3">The presenter(s) was/were knowledgeable and effective. *</label>
<span class="o-label--small">1= Strongly Disagree and 5= Strongly Agree</span>
<div class="o-field__columns">
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback3" value="1" class="o-toggle__field js-toggle-change u-hide required" required="">
<span class="o-toggle__box"></span>
<span class="o-toggle__label u-text-grey">1</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback3" value="2" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">2</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback3" value="3" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">3</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback3" value="4" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">4</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback3" value="5" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">5</span>
</label>
</div><!-- /.o-field__columns -->
<div class="o-error js-error-placement"></div><!-- /.o-error js-error-placement -->
</div><!-- /.o-field -->
<div class="o-field js-toggle-field">
<label class="o-label o-label--large u-mb-2 o-field__label h6 u-text-grey u-text-500" for="feedback4">This activity contained content relevant to my clinical practice. *</label>
<span class="o-label--small">1= Strongly Disagree and 5= Strongly Agree</span>
<div class="o-field__columns">
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback4" value="1" class="o-toggle__field js-toggle-change u-hide required" required="">
<span class="o-toggle__box"></span>
<span class="o-toggle__label u-text-grey">1</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback4" value="2" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">2</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback4" value="3" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">3</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback4" value="4" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">4</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback4" value="5" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">5</span>
</label>
</div><!-- /.o-field__columns -->
<div class="o-error js-error-placement"></div><!-- /.o-error js-error-placement -->
</div><!-- /.o-field -->
<!-- <div class="o-field js-toggle-field">
<label class="o-label o-label--large u-mb-2 o-field__label h6 u-text-grey u-text-500" for="feedback5">The information presented is likely to help change my management strategies in this therapeutic area. *</label>
<span class="o-label--small">1= Strongly Disagree and 5= Strongly Agree</span>
<div class="o-field__columns">
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback5" value="1" class="o-toggle__field js-toggle-change u-hide" required>
<span class="o-toggle__box"></span>
<span class="o-toggle__label u-text-grey">1</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback5" value="2" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">2</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback5" value="3" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">3</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback5" value="4" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">4</span>
</label>
<label class="o-toggle o-toggle--radio o-toggle--radio-numbered o-field__column">
<input type="radio" name="feedback5" value="5" class="o-toggle__field js-toggle-change u-hide">
<span class="o-toggle__box o-toggle__box--large o-toggle__box--radio"></span>
<span class="o-toggle__label u-text-grey">5</span>
</label>
</div>
<div class="o-error js-error-placement"></div>
</div> -->
</div><!-- /.c-feedback -->
</form>Text Content
This content is for healthcare professionals based in the USA only.
Please confirm that you are a healthcare professional in the USA.
Accept
Decline
This activity has been sponsored by Sunovion Pharmaceuticals Inc. Sunovion
Pharmaceuticals Inc. provided financial support and has had input into the
selection of the faculty and the detailed project scope. This activity is
provided by Touch Medical Communications (TMC) for touchNEUROLOGY.
Sign Up / Log In Log Out
ContentsMenu
* Overview & Learning Objectives
* Faculty & Disclosures
* Video Chapters (7)
* Welcome and introduction Time: 00:00
* The impact of OFF Episodes, Including Delayed ON Time: 00:05
* The current treatment approach to OFF Time: 00:10
* Panel discussion: how to identify the type of OFF and select an
intervention Time: 00:15
* Selecting patients: Delphi Panel on the Pharmacological Approach to OFF
Episodes in PD Time: 00:20
* Panel discussion: how to select patients Time: 00:25
* Conclusions and close Time: 00:30
* References
* Downloads
* Leave Feedback
* Back to Learning Zone
Parkinson's Disease, Movement Disorders View Time: TBC
TOUCHROUNDTABLE THE IMPACT OF DELAYED ON: TREATING OFF EPISODES IN PATIENTS WITH
PARKINSON’S DISEASE
Leading experts Stuart Isaacson MD, Yasar Torres-Yaghi MD, Rajesh Pahwa MD
discuss how to reduce the impact of delayed ON in Parkinson’s disease
DR STUART ISAACSON
Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, FL,
USA
CHAIR
PANELISTS:
Dr Yasar Torres-Yaghi, Dr Rajesh Pahwa
0:33
WELCOME AND INTRODUCTION
Dr Isaacson provides an overview of the changing response to levodopa over time
and the types of OFF episodes, which patients may experience.
1/7 Next Chapter
THE IMPACT OF OFF EPISODES, INCLUDING DELAYED ON
Dr Yasar Torres-Yaghi describes the incidence of OFF episodes, the relationship
between quality of life and OFF episodes, and the contribution of delayed ON to
daily OFF time based on data from various studies (including observational
studies) and surveys.
2/7 Next Chapter
THE CURRENT TREATMENT APPROACH TO OFF
Dr Pahwa outlines the goals of treating OFF, the impact of existing therapies on
OFF episodes, and a potential shift in treatment paradigm for OFF episodes.
3/7 Next Chapter
PANEL DISCUSSION: HOW TO IDENTIFY THE TYPE OF OFF AND SELECT AN INTERVENTION
The panel discusses how to identify which type of OFF episodes a patient is
experiencing and how to select an appropriate intervention.
4/7 Next Chapter
SELECTING PATIENTS: DELPHI PANEL ON THE PHARMACOLOGICAL APPROACH TO OFF EPISODES
IN PD
Dr Isaacson provides an overview of the methodology and results of a Delphi
panel to develop a consensus on when on-demand therapies should be considered
for the treatment of OFF episodes.
5/7 Next Chapter
PANEL DISCUSSION: HOW TO SELECT PATIENTS
The panel discusses how to select patients who may benefit from on-demand
therapy.
6/7 Next Chapter
CONCLUSIONS AND CLOSE
The panel conclude discussions with the key take-home messages.
7/7 Leave Feedback
* Overview & Learning Objectives
* Faculty & Disclosures
* References
* Downloads
Leave Feedback
LEARNING OBJECTIVES & OVERVIEW
OVERVIEW
The consistent beneficial effect of each levodopa dose is reduced with
Parkinson’s disease progression leading to increased frequency of cycling
between ON and OFF states.1 OFF episodes can result from delayed onset of
response to a levodopa dose (delayed ON).1 On-demand treatments can provide an
acute conversion from OFF to ON for all types of OFF episodes, and can serve as
a complementary therapy to address delayed time to ON.1–5 In this activity,
leading experts provide guidance on when to use on-demand therapy and which
patients may benefit.
LEARNING OBJECTIVES
After watching this activity, participants should be better able to:
* Outline the impact of delayed ON in the context of the total daily OFF time
experienced by a patient.
* Discuss potential changes in treatment approach based on the type of OFF
experienced by patients.
* Identify patients who may benefit from an on-demand therapy for OFF based on
the findings of an expert consensus panel.
FACULTY & DISCLOSURES
DR STUART ISAACSON
Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, FL,
USA
Dr Isaacson is a neurologist specializing in Parkinson’s disease and movement
disorders, and Medical Director of the Parkinson’s Research and Education
Foundation. He has been involved in over 75 clinical trials and has authored or
nearly 100 journal articles, book chapters and abstracts. He has also served on
national and international committees for drug development programs and trials,
as well as for the Parkinson Study Group and the movement disorders section of
the American Academy of Neurology.
Honoraria for CME, consultant, research grants, and/or promotional speaker on
behalf of: Abbvie, Acadia, Acorda, Adamas, Addex, Affiris, Alexza, Allergan,
Amarantus, Amneal, Aptinyx, Axial, Axovant, Benevolent, Bial, Biogen, Biovie,
Britannia, Cadent, Cala, Cerecor, Cerevel, Cipla, Eli Lilly, Enterin, GE
Healthcare, Global Kinetics, Impax, Impel, Intec Pharma, Ipsen, Jazz, Kyowa
Kirin, Lundbeck, Merz, Michael J. Fox Foundation, Mitsubishi Tanabe, Neuralys,
Neurocrine, Neuroderm, Novartis, Parkinson Study Group, Pharma2B, Praxis,
Prilenia, Promentis, Revance, Roche, Sage, Sanofi, Scion, Stoparkinson,
Sunovion, Sun Pharma, Supernus, Teva, Theravance and Transposon.
DR YASAR TORRES-YAGHI
Department of Neurology, Medstar Georgetown University Hospital, Washington D.C,
USA
Dr Torres-Yaghi is an expert in movement disorders at Medstar Georgetown
University Hospital. He completed a fellowship at MedStar Georgetown University
Hospital in neuro-restoration research. Dr Torres-Yaghi is also leading a
research initiative to care for aging patients with neurodegenerative conditions
with overlapping features of both cognitive impairment and Parkinson’s disease.
Honoraria from Sunovion.
DR RAJESH PAHWA
University of Kansas Medical Center, Movement Disorders Division, Kansas City,
KS, USA
Dr Rajesh Pahwa is Professor of Neurology and Director of Parkinson Foundation
Center of Excellence at the University of Kansas Medical Center. He has
conducted more than 75 clinical trials related to Parkinson’s disease and other
movement disorders and published more than 250 peer-reviewed articles, chapters
and abstracts in leading neurology and movement disorder journals.
Consultant for Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Artemida,
Avion, BioVie, CalaHealth, Global Kinetics, Insightec, Jazz, Kyowa, Neurocrine,
Neuroderm, PhotoPharmics, Sage, Sunovion, Supernus, UCB and Wren. Research
support from Abbott, AbbVie, Addex, Biogen, Biohaven, Boston Scientific, EIP,
Global Kinetics, Impax, Intec, Lilly, Neuroderm, Neuraly, Parkinson’s
Foundation, Pharma 2B, Prelinia, Roche, Sage, SIS, Sun Pharma, Sunovion,
Theranexus, Theravance, and Voyager.
REFERENCES
REFERENCES
1. Vijiaratnam N, Foltynie T. Therapeutic Strategies to Treat or Prevent Off
Episodes in Adults with Parkinson's Disease. Drugs 2020; 80(8): 775-96.
2. Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease
patients: Opportunities and choices. Postgrad Med 2021; 133(7): 721-7.
3. Hui JS, Fox SH, Neeson W, et al. Open-label titration of apomorphine
sublingual film in patients with Parkinson's disease and "OFF" episodes.
Parkinsonism Relat Disord 2020; 79: 110-6.
4. Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off
episodes in Parkinson's disease: a randomised, double-blind,
placebo-controlled phase 3 study. Lancet Neurol 2020; 19(2): 135-44.
5. Isaacson S. Use of on-demand treatments for off episodes in parkison’s
disease: guidance from a rand/ucla modified delphi consensus panel. 4th Pan
American Parkinson’s Disease and Movement Disorders Congress (PAS); 2022
May 26-28, 2022; Miami, USA; 2022.
6. Armstrong MJ and Okun MS. Diagnosis and Treatment of Parkinson Disease: A
Review. JAMA. 2020;323:548-560.
7. Adler CH. Relevance of motor complications in Parkinson's disease.
Neurology. 2002;58(4 suppl 1):S51-S56.
8. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor
fluctuations as estimated from the cumulative literature. Mov Disord.
2001;16(3):448-458.
9. Chou KL, Stacy M, Simuni T, et al. The spectrum of "off" in Parkinson's
disease: What have we learned over 40 years? Parkinsonism Relat Disord.
2018;51:9-16.
10. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of
Parkinson's disease on the quality of life. Mov Disord. 2005;20:224-230.
11. Elmer LW, Juncos JL, Singer C, et al. Pooled Analyses of Phase III Studies
of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in
Parkinson's Disease. CNS Drugs. 2018;32:387-398.
12. Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in
Parkinson's disease. Lancet Neurol. 2015;14:625-639.
13. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa
in patients with Parkinson's disease and end-of-dose motor fluctuations: a
randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154-165.
14. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and
movement disorder society evidence-based medicine review: Update on
treatments for the motor symptoms of Parkinson's disease. Mov Disord.
2018;33:1248-1266.
15. Hauser RA Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa
(CVT-301) for early morning OFF periods in Parkinson's disease.
Parkinsonism Relat Disord. 2019;64:175-180.
16. Hui JS, Fox SH, Neeson W, et al. Open-label titration of apomorphine
sublingual film in patients with Parkinson's disease and "OFF" episodes.
Parkinsonism Relat Disord. 2020;79:110-116.
17. Isaacson S, Lew M, Ondo W, et al. Apomorphine Subcutaneous Injection for
the Management of Morning Akinesia in Parkinson's Disease. Mov Disord Clin
Pract. 2017;4:78-83.
18. Isaacson SH, Pahwa R, Pappert EJ, et al. Should "on-demand" treatments for
Parkinson's disease OFF episodes be used earlier? Clin Park Relat Disord.
2022;6:100145.
19. Isaacson SH, Achari M, Bhidayasiri R, et al. Use of on-demand treatments
for OFF episodes in Parkinson’s disease: guidance from a RAND/UCLA modified
Delphi consensus panel. Presented at: 4th Pan American Parkinson’s Disease
and Movement Disorder Congress (PAS); May 26-28, 2022; Miami, FL USA.
Poster 123.
20. Leenders KL, Poewe WH, Palmer AJ, et al. Inhibition of L-[18F]fluorodopa
uptake into human brain by amino acids demonstrated by positron emission
tomography. Ann Neurol. 1986;20:258-262.
21. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist
istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a
double-blind, randomized, multicenter clinical trial (6002-US-005). Ann
Neurol. 2008;63:295-302.
22. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in
advanced Parkinson's disease: results of a double-blind,
placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
23. Magrinelli F, Picelli A, Tocco P, et al. Pathophysiology of Motor
Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and
Rehabilitation. Parkinsons Dis. 2016:9832839.
24. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in
patients with Parkinson disease and ON/OFF motor fluctuations. Clin
Neuropharmacol. 2003;26:196-198.
25. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on
levodopa pharmacokinetics in Parkinson disease patients. Clin
Neuropharmacol. 2006;29:61-67.
26. Nijhuis FAP, van den Heuvel L, Bloem BR, et al. The Patient's Perspective
on Shared Decision-Making in Advanced Parkinson's Disease: A
Cross-Sectional Survey Study. Front Neurol. 2019;10:896.
27. Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of
motor complications in Parkinson's disease. Neurology. 2000;55(suppl
4):S13-S20.
28. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the
treatment of Parkinson disease (2009). Neurology. 2009;72(21 suppl
4):S1-S136.
29. Olanow CW, Poewe W, Rascol O, et al. On-Demand Therapy for OFF Episodes in
Parkinson's Disease. Mov Disord. 2021;36:2244-2253.
30. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release:
randomized, controlled study in advanced Parkinson disease. Neurology.
2007;68:1108-1115.
31. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa
in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting
effect in Adjunct therapy with Rasagiline Given Once daily, study): a
randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
32. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor
function in parkinsonian patients with the "wearing-off" phenomenon: a
double-blind, placebo-controlled, multicenter trial. Neurology.
1997;49:1066-1071.
33. Reimer J, Grabowski M, Lindvall O, et al. Use and interpretation of on/off
diaries in Parkinson's disease. J Neurol Neurosurg Psychiatry.
2004;75:396-400.
34. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to
levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study
Group. Neurology. 1998;51:1309-1314.
35. Stocchi F, Coletti C, Bonassi S, et al. Early-morning OFF and levodopa dose
failures in patients with Parkinson's disease attending a routine clinical
appointment using Time-to-ON Questionnaire. Eur J Neurol. 2019;26:821-826.
36. Suttrup I, Suttrup J, Suntrup-Krueger S, et al. Esophageal dysfunction in
different stages of Parkinson's disease. Neurogastroenterol Motil.
2017;29(1).
37. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth
in Parkinson's disease. Parkinsonism Relat Disord. 2014;20:535-540.
38. Thach A, Jones E, Pappert E, et al. Real-world assessment of the impact of
"OFF" episodes on health-related quality of life among patients with
Parkinson's disease in the United States. BMC Neurol. 2021;21:46.
39. Thach A, Zichlin M, Peddle M, et al. Systematic literature review of key
outcomes used to assess adjunctive treatments for Parkinson’s disease.
Presented at: International Parkinson’s Disease and Movement Disorder
Society Congress (MDS); 15–18 September, 2022; Madrid, Spain. Poster 783.
DOWNLOADS
View and download resources from this activity to support your learning and
share with colleagues
Download Slides
JOURNAL ARTICLES AND MORE TO YOUR INBOX
--------------------------------------------------------------------------------
Get the latest clinical insights from touchNEUROLOGY
Sign me up!
THIS ACTIVITY IS SPONSORED
This activity has been sponsored by Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc. provided financial support and has had input into
the selection of the faculty and the detailed project scope.
This activity is provided by Touch Medical Communications (TMC) for
touchNEUROLOGY.
TMC activities are developed in conjunction with expert faculty.
Unapproved products or unapproved uses of approved products may be discussed by
the faculty; these situations may reflect the approval status in one or more
jurisdictions. The presenting faculty have been advised by TMC to ensure that
they disclose any such references made to unlabelled or unapproved use. No
endorsement by TMC or Sunovion Pharmaceuticals Inc. of any unapproved products
or unapproved uses is either made or implied by mention of these products or
uses in TMC activities. TMC accepts no responsibility for errors or omissions.
The views and opinions expressed are those of the faculty and do not necessarily
reflect those of TMC or Sunovion Pharmaceuticals Inc.
Launch date: January 2023
MI-KYN-00151
Feedback Close
FEEDBACK
Please provide feedback for this touchROUNDTABLE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):
* = Mandatory Field
This activity was of high quality. * 1= Strongly Disagree and 5= Strongly Agree
1 2 3 4 5
This activity met the stated educational objectives. * 1= Strongly Disagree and
5= Strongly Agree
1 2 3 4 5
The presenter(s) was/were knowledgeable and effective. * 1= Strongly Disagree
and 5= Strongly Agree
1 2 3 4 5
This activity contained content relevant to my clinical practice. * 1= Strongly
Disagree and 5= Strongly Agree
1 2 3 4 5
Send Feedback
Feedback Close
FEEDBACK
Thank you for your feedback.
Back to Activity
Copied to clipboard!
accredited
arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down
Clicky Media
Logoconsultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots
nurse-consultantpadlock
patient-advocate-pathologistpatient-consultantpatientperson
pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter
scenerysearch share single-doctor
social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star
(1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar
Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM
Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate
Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services
Icons-12Salary £
TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
We need your consent before you can continue on our website. We use cookies and
other technologies on our website. Some of them are essential, while others help
us to improve this website and your experience. Personal data may be processed
(e.g. IP addresses), for example for personalized ads and content or ad and
content measurement. You can find more information about the use of your data in
our privacy policy. You can revoke or adjust your selection at any time under
Settings.
Accept All
Individual Cookie Preferences
Cookie Preferences
We use cookies and other technologies on our website. Some of them are
essential, while others help us to improve this website and your experience.
Personal data may be processed (e.g. IP addresses), for example for personalized
ads and content or ad and content measurement. You can find more information
about the use of your data in our privacy policy. Here you will find an overview
of all cookies used. You can give your consent to whole categories or display
further information and select certain cookies.
Accept all Save
Back
Cookie Preferences
Essential (5)
These are cookies that are required for the operation of the website.
Show Cookie Information Hide Cookie Information
Name Cookie Management Preferences Provider Owner of this website Purpose Saves
the visitor's preferences selected in the Cookie Management preferences Cookie
Name borlabs-cookie Cookie Expiry 1 Year
Name Login and Security Provider Touch Medical Media Services Ltd Purpose
WordPress uses cookies to verify who you are. There are cookies for logged in
users and for commenters Privacy Policy
https://www.touchmedicalmedia.com/privacy-policy/ Host(s) touchcardio.com,
touchcardioime.org, touchcardiotmc.com, touchendocrinology.com,
touchendocrinologyime.org, touchendocrinologytmc.com, touchime.org,
touchimmunology.com, touchimmunologyime.org, touchimmunologytmc.com,
touchinfectiousdiseases.com, touchinfectiousdiseasesime.org,
touchinfectiousdiseasestmc.com, touchmedicalcommunications.com,
touchmedicalmedia.com, touchneurology.com, touchneurologyime.org,
touchneurologytmc.com, touchoncology.com, touchoncologyime.org,
touchoncologytmc.com, touchophthalmology.com, touchophthalmologyime.org,
touchophthalmologytmc.com, touchrespiratory.com, touchrespiratoryime.org,
touchrespiratorytmc.com Cookie Name wordpress_test_cookie, wordpress_sec_,
wordpress_logged_in_ Cookie Expiry Current session
Name Touch Medical Essential Provider Touch Medical Media Services Ltd Purpose
These cookies are used to verify user login and provide essential site
functionality. Privacy Policy https://www.touchmedicalmedia.com/privacy-policy/
Host(s) touchcardio.com, touchcardioime.org, touchcardiotmc.com,
touchendocrinology.com, touchendocrinologyime.org, touchendocrinologytmc.com,
touchime.org, touchimmunology.com, touchimmunologyime.org,
touchimmunologytmc.com, touchinfectiousdiseases.com,
touchinfectiousdiseasesime.org, touchinfectiousdiseasestmc.com,
touchmedicalcommunications.com, touchmedicalmedia.com, touchneurology.com,
touchneurologyime.org, touchneurologytmc.com, touchoncology.com,
touchoncologyime.org, touchoncologytmc.com, touchophthalmology.com,
touchophthalmologyime.org, touchophthalmologytmc.com, touchrespiratory.com,
touchrespiratoryime.org, touchrespiratorytmc.com Cookie Name TouchUserStatus,
tmm_user_logged_in, DBUV-I, DBUV-U, DBUV-P, DBUV-E, DBUV-N, DBUV-B, DBUV-V,
SSO-I, SSO-E, SSO-X, SSO-V, sso_logged_in, wfwaf-authcookie-, wp_wpfileupload_
Cookie Expiry Current session
Name Google AdSense Provider Google Ireland Limited, Gordon House, Barrow
Street, Dublin 4, Ireland Purpose Cookie by Google used for ad targeting and ad
measurement. Privacy Policy https://policies.google.com/privacy?hl=en Host(s)
doubleclick.net Cookie Name DSID, IDE Cookie Expiry 1 Year
Name Google Tag Manager Provider Google Ireland Limited, Gordon House, Barrow
Street, Dublin 4, Ireland Purpose Cookie by Google used to control advanced
script and event handling. Privacy Policy
https://policies.google.com/privacy?hl=en Host(s) google.co.uk, google.com
Cookie Name _ga,_gat,_gid Cookie Expiry 2 Years
Optional (2)
Optional
These cookies allow us to recognise and count the number of visitors and to see
how visitors move around our website, record the pages you have visited and the
links you have followed, and recognise you when you return to our website. We
will use this information to make our website and the advertising displayed on
it more relevant to your interests and to remember your preferences.
Show Cookie Information Hide Cookie Information
Accept Facebook Pixel Name Facebook Pixel Provider Meta Platforms Ireland
Limited, 4 Grand Canal Square, Dublin 2, Ireland Purpose Cookie by Facebook used
for website analytics, ad targeting, and ad measurement. Privacy Policy
https://www.facebook.com/policies/cookies Cookie Name
_fbp,act,c_user,datr,fr,m_pixel_ration,pl,presence,sb,spin,wd,xs Cookie Expiry
Session / 1 Year
Accept Clarity Name Clarity Provider Microsoft Purpose User flow and user
experience tracking to implement improvements and make your experience better.
Privacy Policy https://clarity.microsoft.com/terms Host(s) clarity.ms,
www.clarity.ms Cookie Name CLID,MUID Cookie Expiry 1 Year
Privacy Policy